Wegovy and Foundayo are GLP-1 receptor agonists
It encourages gradual fat loss while preserving lean muscle
Compound Comparison Table Published Scientific Literature Retatrutide has been referenced in published scientific investigations involving metabolic pathway research, incretin biology, receptor signaling, and triple-receptor agonist models
FDA-Approved Eligibility Criteria: Primary Qualification (BMI-Based): You qualify if: BMI 30 (obesity category), OR BMI 27 (overweight category) PLUS at least one weight-related health condition BMI Reference Guide: Weight-Related Health Conditions (For BMI 27-29.9): Qualifying conditions include: Type 2 diabetes or prediabetes Hypertension (high blood pressure) High cholesterol or dyslipidemia Obstructive sleep apnea Cardiovascular disease Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease Osteoarthritis exacerbated by weight If you have BMI 27-29.9 with any of these conditions, you qualify
If youre microdosing, using FDA-approved brand-name medications with your doctors guidance is significantly safer than compounded alternatives
Furthermore, what if employers that offer self-insured plans to their employees and dependents follow suit
